Gene therapy on the move. Issue 11 (17th September 2013)

• Record Type: Journal Article
• Authors: Kaufmann, Kerstin B.; Büning, Hildegard; Galy, Anne; Schambach, Axel; Grez, Manuel
• Is Part Of: EMBO molecular medicine. Volume 5:Issue 11(2013:Nov.)
• Page Start: 1642
• Page End: 1661
• Publication Date: 2013-09-17
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.1002/emmm.201202287
• Languages: English
• ISSNs: 1757-4676

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="emmm201202287-sec-0001" sec-type="section"> <p>The first gene therapy clinical trials were initiated more than two decades ago. In the early days, gene therapy shared the fate of many experimental medicine approaches and was impeded by the occurrence of severe side effects in a few treated patients. The understanding of the molecular and cellular mechanisms leading to treatment‐ and/or vector‐associated setbacks has resulted in the development of highly sophisticated gene transfer tools with improved safety and therapeutic efficacy. Employing these advanced tools, a series of Phase I/II trials were started in the past few years with excellent clinical results and no side effects reported so far. Moreover, highly efficient gene targeting strategies and site‐directed gene editing technologies have been developed and applied clinically. With more than 1900 clinical trials to date, gene therapy has moved from a vision to clinical reality. This review focuses on the application of gene therapy for the correction of inherited diseases, the limitations and drawbacks encountered in some of the early clinical trials and the revival of gene therapy as a powerful treatment option for the correction of monogenic disorders.</p> </sec> </abstract>